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Background: A subgroup of patients with chronic cough is recognised as having airway symptoms resulting
exposure to chemicals and scents related to enhanced cough sensitivity to inhaled capsaicin. Sensory
hyperreactivity, which has an estimated prevalence of more than 6%, is one possible explanation for the symptoms
experienced by these patients. We hypothesized that a number of patients diagnosed with chronic unexplained
cough also have coughing provoked by chemical irritants associated with augmented capsaicin cough reaction, but
the extent of such a relation is not known. One aim of the present study was to analyse cough sensitivity to
inhaled capsaicin in patients with chronic unexplained cough. Another aim was to compare capsaicin sensitivity in
individuals with chemically induced coughing (the chemical-sensitive group) to capsaicin sensitivity in those
without such chemical sensitivity (non-sensitive group).
Methods: Fifty-six participants from an earlier cross-sectional study of 62 patients with chronic unexplained cough
were asked to participate in this study: 33 were chemical-sensitive and 23 were non-sensitive. Each participant
visited the clinic once and performed a capsaicin inhalation test with one of two inhalation devices. The number of
coughs, induced airway symptoms, and spirometry results were recorded.
Results: Thirty-nine of the invited patients participated in the study, with 32 in the chemical-sensitive group (21
women, 11 men), and 7 in the non-sensitive group (4 women, 3 men). The chemical-sensitive patients coughed
significantly more on inhaling capsaicin, and had significantly more other airway symptoms compared to those in
the non-sensitive group. Women coughed significantly more than men after receiving the higher concentration of
capsaicin.
Conclusions: Environmental irritants often trigger chronic unexplained cough. The current findings confirm that
this sensitivity is related to enhanced capsaicin cough sensitivity and indicates more involvement of airway sensory
nerves in the pathophysiology of the disease than in cough without evident trigger factors.
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About 10-38% of patients seeking medical care in re-
spiratory clinics report coughing as a symptom [1,2].
Individuals suffering from cough, show a high level of
morbidity and a high rate of healthcare utilization, and
cough has a negative impact on patients’ health-related
quality of life [3-6]. Cough is regarded as chronic when
it persists for more than 8 weeks [7]. Common causes of
chronic cough include asthma, gastroesophageal reflux
disease (GERD), and post-nasal drip syndrome [8]. After* Correspondence: ewa.ternesten@lungall.gu.se
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distribution, and reproduction in any mediumall possible underlying causes of cough have been
excluded and the patients have been treated according
to current guidelines, a group of patients, mainly female,
remains that can be labelled as having chronic refractory
unexplained cough. This cough is often triggered by
talking, laughing, singing, or strong chemicals and scents
from perfume, cigarette smoke, and cooking [9,10].
More knowledge is needed about cough induced by such
irritants.
Sensory hyperreactivity (SHR) is one explanation for
cough and other airway symptoms induced by exposure
to chemicals and scents [11,12]. However, the extent to
which SHR could help explain the symptoms experienceded Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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known. Common symptoms of SHR are cough, heavy
breathing, difficulty getting air, phlegm, throat irritation,
hoarseness, rhinorrhoea, and eye irritation [11-13]. SHR is
most common among women (70%), and a Swedish
population-based study estimated its prevalence to be
more than 6% among adults [14]. Patients with SHR can
be identified through a capsaicin provocation test. Several
studies have shown this test has good short-term and
long-term reproducibility and the ability to distinguish be-
tween patients with SHR and those with asthma and those
who are healthy controls [11-13,15].
Capsaicin, the main pungent ingredient in chilli, is a
well-known cough-inducing agent when inhaled [16-19].
It is a noxious and odourless vanilloid, which stimulates
the unmyelinated C-fibres of the sensory nervous system
and produces a burning sensation by activating the ion
channel transient receptor vanilloid subunit 1 (TRPV1)
[20]. The TRPV1 channel is activated not only by capsa-
icin, but also by noxious stimuli and heat; it is
potentiated by extracellular acidic pH, and interacts with
vanilloid compounds [21]. Patients with chronic cough
have increased expression of TRPV1 and a significant
correlation between capsaicin response and the number
of TRPV1-positive nerves [22]. A heightened cough sen-
sitivity to inhaled capsaicin has been found in patients
with chronic cough, in cases where the cause of the
cough is known and where it is unknown [23].
We hypothesized that a number of patients diagnosed
with chronic unexplained cough also have coughing
provoked by chemical irritants associated with augmented
capsaicin cough reaction but the extent of such a relation
is not known. To further explore this, a capsaicin inhal-
ation test could be applied. One aim of the present study
was to analyse cough sensitivity to inhaled capsaicin in
patients with chronic unexplained cough. The patients
had been selected from an earlier cross-sectional study
[6]. Another aim was to compare capsaicin sensitivity in
individuals with chemically induced airway symptoms (the
chemical-sensitive group) to capsaicin sensitivity in those
without such chemical sensitivity (non-sensitive group).
Methods
Patients
Fifty-six patients from an earlier cross-sectional study
that included 62 patients with chronic unexplained
cough were randomly selected and invited to participate
in this study [6]. The group included 33 chemical-sensitive
patients and all of the 23 non-sensitive individuals. The
earlier study had already excluded all patients with diseases
such as asthma, chronic obstructive pulmonary disease
and pulmonary fibrosis that could cause cough and all
patients diagnosed with allergy, rhinitis, post-nasal drip
syndrome, or any kind of GERD, those making any use ofangiotensin-converting enzyme inhibitors or medication
for GERD, and current smokers. This study excluded any-
one who was pregnant or breastfeeding.Study design
The participants were contacted by phone. Informed
consent was obtained from all participants after they
were provided with verbal and written information. The
study was approved by the Regional Ethical Review
Board of Gothenburg, Sweden.
The participants visited the clinic once and all of them
were again screened using a local questionnaire that
asked whether they had airway symptoms from chemicals
and scents (yes/no) [6]. None of the patient had
performed a capsaicin inhalation test before they were
included in the study. Provocations were not performed in
patients who had experienced respiratory infections dur-
ing the past month. Before the capsaicin provocations, all
medication was withheld for at least 6 h.
The capsaicin challenges were performed with a
standardized method [11-15] with one of two different
air-driven devices: Pari Boy (Paul Ritzau Pari-Werk,
GmbH, Starnberg, Germany) or Maxin MA3 (Clinova
Medical AB, Malmö, Sweden). The two different inhal-
ation devices were used because the allergy clinic
switched from using the Pari Boy to using the Maxin
MA3 over the period of studies. These devices are com-
patible in terms of the limits set for a positive capsaicin
inhalation test, but use different capsaicin concentration
levels [15].
In each challenge the participant inhaled saline followed
by two concentrations of capsaicin, the second being
stronger than the first. The order of the given
concentrations was known by the nurse performing the
tests but the patients were not told that the capsaicin
concentrations would increase during the provocations.
The total time for each provocation was about 35 minutes.
In accordance with the earlier established limits for
capsaicin cough sensitivity [12,14], the cut-off values for
a positive capsaicin inhalation test for the diagnosis of
SHR was set to 10 coughs at the lower capsaicin
concentrations (0.4 and 0.06 μmol/L) or 35 coughs at
the higher capsaicin concentrations (2.0 and 0.3 μmol/
L), with both the devices [12,14,15].Capsaicin provocation
A stock solution of capsaicin (1 mmol/L in ethanol
[99.5%] from Sigma-Aldrich Sweden AB, Stockholm,
Sweden) was prepared. From this stock solution, aque-
ous provocation solutions were prepared in accordance
with earlier studies; the solutions were 0.4 and 2.0 μmol/
L for the Pari Boy device and solutions of 0.06 and 0.3 -
μmol/L for the Maxin MA3 device. The number of
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of inhalation of each provocation solution [13,15].
In the case of the Pari Boy device, the device was filled
first with 1 mL of saline and then two capsaicin
concentrations [11-13,15]. The participants were instructed
to inhale with tidal volume breathing without a nose-clip,
to completion or for a maximum of 6 min, following by a
4 min rest.
The Maxin MA3 device was filled first with 2 mL sa-
line and then the two capsaicin concentrations. The de-
vice nebulizes continually, and provides a fixed constant
flow of 0.25 mL/min. The participants were instructed
to inhale with tidal volume breathing without a nose-
clip for 4 min, followed by 6 min rest, consequently they
inhaled a total of 1 mL provocation solution [15].
Before and after the capsaicin provocation, the
participants evaluated their symptoms on a scale of 0–3 (0,
no symptoms; 1, mild symptoms; 2, moderate symptoms;
and 3, severe symptoms). Eight symptoms were analysed:
heavy breathing, difficulty getting air, chest pressure,
phlegm, throat irritation, hoarseness, rhinorrhoea, and eye
irritation [11,24,25].
Forced expiratory volume during 1 s (FEV1) was
measured before and after each capsaicin provocation
(Vitalograph, Buckingham, UK), and the highest of two
values was recorded.Statistical methods
All data were analysed using version 17 of the SPSS soft-
ware package (SPSS, Inc., Chicago, IL, USA). Data are
presented as mean values with standard deviation (SD)
and median values. Results were considered significant
at a p value of < 0.05. The Mann–Whitney U-test was
used for non-paired data, and the Wilcoxon signed-rank
test for paired data.
In accordance with dose-response relationships seen in
earlier studies, missing data for participants whose
provocation was halted due to excess coughing were
filled in by doubling the number of coughs evoked by
the lower capsaicin concentrations to represent the
cough response to the higher capsaicin concentrations
[11,13,15].Table 1 Demographic data for 39 patients with chronic
cough
Characteristics Patients (n = 39)
Sex, female/male (n) 25/14
Chemical-sensitive/non-sensitive (n) 32/7
Age, years 53.8 (12.6)
Duration of cough symptoms, years 9.4 (6.2)
Smoking status (n)
Never/previous 24/15
Data are presented as mean and standard deviation (SD) for age and duration
of cough symptoms, and otherwise as number (n).Results
Of the 56 patients invited to participate, 17 were
excluded due to recovery from their coughing: 2 were in
the chemical-sensitive group (n = 33) and 11 were in the
non-sensitive group (n = 23). In the non-sensitive group,
3 others were excluded because of difficulty in taking
time away from work, and 1 because of azithromycin
treatment for airway symptoms. All of the chemical-
sensitive patients reported persistent sensitivity and one
of the previously non-sensitive patients reportedsymptoms from chemicals and scents and was
reassigned to the chemical-sensitive group.
The final analyses was done on the data from 39
patients, 32 (mean age 54.7 [10.8]) in the chemical-
sensitive group (21 women and 11 men), and 7 (mean
age 49.4 [19.5]) in the non-sensitive group (4 women
and 3 men). The demographic data of the study group
are shown in Table 1. All patients except for two had
had a negative methacholine inhalation test within the
last five years, in accordance with international
guidelines [26,27]. Of the 39 patients, 5 regularly used
inhaled corticosteroids, 4 inhaled β2-agonists, 1 inhaled
anticholinergic, and 8 used morphine derivate syrup.Capsaicin provocation
Nine patients in the chemical-sensitive group had under-
gone the capsaicin inhalation test four years earlier with
the Pari Boy device [11-13,15], and that data were used
in this study. The remaining 30 patients (23 from the
chemical-sensitive group, and 7 from the non-sensitive
group) were tested using the Maxin MA3 device [15].
All 39 patients tried to inhale the lower concentrations
of capsaicin (0.4 and 0.06 μmol/L for the Pari Boy device
and the Maxin MA3 device respectively); 5 patients in
the chemical-sensitive group discontinued the provoca-
tion because of having more than 35 coughs. All patients
in the non-sensitive group inhaled both the low and the
high capsaicin concentrations. The chemical-sensitive
group coughed significantly more than the non-sensitive
group on the lower concentrations of capsaicin (p <
0.05). In the chemical-sensitive group, the median num-
ber of coughs was 13 for the lower concentrations (0.4
or 0.06 μmol/L) and 37.5 for the higher concentrations
(2.0 or 0.3 μmol/L). The corresponding values for the
non-sensitive group were 5 and 15, respectively. The
results of the capsaicin provocations are presented in
Figure 1.
Twenty two (69%) of the patients in the chemical-
sensitive group had a positive capsaicin inhalation test,
and met the diagnostic criteria for SHR [12,14]. In the
Figure 1 Box plot presentation of cough response in 39
patients with chronic cough after inhalation of lower (0.4 or
0.06 μmol/L) and higher (2.0 or 0.3 μmol/L) capsaicin
concentrations. The horizontal line in the centre of each box is the
median. The top and bottom of the box represent the 25th and
75th percentiles, and whiskers indicate the 10th and 90th
percentiles. Circles show individual maximum and minimum
data points.
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capsaicin inhalation test.
Women coughed significantly more than men on in-
haling the higher concentrations of capsaicin (p < 0.05).
For women the median number of coughs was 10 at the
lower concentrations of capsaicin and 55 at the higher
concentrations. The corresponding values for men were
6.5 and 23.5 respectively.
The capsaicin provocation also induced significantly
greater symptoms in the chemical-sensitive group for
heavy breathing (p < 0.001), difficulty getting air (p <
0.01), chest pressure (p < 0.05), phlegm (p < 0.05), throat
irritation (p < 0.01), hoarseness (p < 0.01), rhinorrhoea (p
< 0.001), and eye irritation (p < 0.05). In the non-
sensitive group, the capsaicin provocation induced sig-
nificantly more (p < 0.05) throat irritation.
The basic mean FEV1 was 102.4% (18.4) of predicted
value in the chemical-sensitive group and 103.8% (14.9)
of predicted value in the non-sensitive group (ns), and
did not change after any capsaicin provocation.
Discussion
The main finding of this study was that environmental
irritants are often triggering factors in chronic unex-
plained cough and cough sensitivity to inhaled capsaicin
was higher in chemical-sensitive patients than in non-
sensitive patients. We also found that 22 (69%) of the
patients in the chemical-sensitive group had a positive
capsaicin inhalation test, and met the diagnostic criteria
for SHR [12,14]. In the non-sensitive group, only 3 of 7
patients (43%) had a positive capsaicin inhalation test.
Further, in comparison to previous studies the results in-
dicate higher capsaicin sensitivity in the non-sensitive
group than in earlier tested healthy controls [28,29], butthe present non-sensitive group is too small to draw any
major conclusions. The study included twice as many
women as men, and the study results are in accordance
with previous reports of women being over-represented
in cough clinics [9] and being more sensitive to inhaled
capsaicin [30,31].
A total of 13 patients had been excluded from partici-
pating because they had recovered from their cough.
Eleven belonged to the non-sensitive group, constituting
48% of the non-sensitive individuals. This indicates a
possibility of recognising a group of cough patients who
have symptoms induced by environmental irritants and
who are at risk of having the problems last for several
years. However, although increasing evidence suggests
environmental irritants are important factors in chronic
cough [10,32-34], larger groups of patients need to be
studied to find out whether chemical sensitivity is essen-
tial for long-lasting symptoms to occur.
The use of two devices, the Pari Boy and Maxin MA3
could be perceived as a limitation. However, an earlier
study showed that the Pari Boy and the Maxin MA3 de-
vice, which we used in the present study, can be used
interchangeably to estimate levels of neural sensory re-
activity, and there was good agreement between the
cough results of capsaicin with the two devices [15].
Each provocation method had also a good ability to dis-
tinguish patients with SHR from healthy controls, al-
though the Maxin MA3 device showed even higher
degree of discriminative ability between patients with
SHR and healthy control [11,15].
The capsaicin inhalation test is non-specific because of
the huge variation in capsaicin cough sensitivity among
healthy individuals and in the different conditions
affecting the airways [18,35]. The patients in the present
study were carefully examined and other causes of cough
were excluded. To avoid bias, international guidelines
recommend capsaicin concentrations be given randomly,
and that saline be randomly interspersed between incre-
mental concentrations of capsaicin [36]. Previous studies
have, however, shown that the order in which capsaicin
concentrations are given is of importance for the cough
outcome of capsaicin provocations [14,18] and that in
patients with SHR even inhalation of saline induced
coughing [11,37]; these findings influenced our choice
of method, with first saline and then low and high
concentration of capsaicin being given. Furthermore
the participants had not previously been tested with
capsaicin and they were not told that the capsaicin
concentrations would increase during the provocation.
In our experience, the capsaicin inhalation test used
herein with tidal breathing is a stable and reproducible
method, and represents an objective test to measure
sensory reactivity in the airways. The limits used for a
positive capsaicin inhalation test were in accordance
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[12,14].
Researchers have sharply disagreed on the cause of
chronic unexplained cough [38,39], which included post-
nasal drip syndrome [1] and GERD [40,41]. During the
last decade, however, a more common view seems to
have developed [42] and the post-nasal drip syndrome is
now often replaced with a more general description,
‘upper airway cough syndrome’ [43]. The upper and
lower airways are viewed as being closely related and
complementing each other with regard to reflexes
[44-46]. This close connection is also evident in regard
to chronic cough. The cough hypersensitivity syndrome
is a new paradigm that accounts for unexplained cough
and includes several groups of chronic cough patients,
both those with symptoms that may indicate a reflux
disease and those with a general hypersensitivity to-
wards, for example, environmental irritants [32,33,47].
The current study demonstrates that an association
exists between the upper airways and chronic cough, be-
cause many patients also had rhinitis symptoms after the
capsaicin provocations. It also shows a general airway
hypersensitivity linked to increased capsaicin cough
sensitivity.
Conclusions
Environmental irritants often trigger chronic unex-
plained cough. The current findings confirm that this
sensitivity is related to enhanced capsaicin cough sensi-
tivity and indicates more involvement of airway sensory
nerves in the pathophysiology of the disease than in
cough without evident trigger factors.
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